Did You Know...
...that to encourage use of his new invention, the shopping cart, market owner Sylvan Goldman hired fake shoppers to push the carts around his store in Oklahoma City? Seems his customers were reluctant to give up their hand-carried baskets.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8110192 | Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope ... | 02/07/2012 |
| 7993647 | Monoclonal antibodies to HIV-1 and methods of using same The present invention provides monoclonal antibodies to HIV-1 Vpr and hybridoma cell lines that produce the monoclonal antibodies to HIV-1 Vpr. Methods for use of such antibodies in the detection of HIV-1 infection are also provided. ... | 08/09/2011 |
| 7744887 | Human antibodies interacting with HIV gp41 Human scFvs are disclosed which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to neutralize diverse HIV isol... | 06/29/2010 |
| 7595050 | Human IGM monoclonal antibody capable of inducing apoptosis in HIV-infected cells A monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis is obtained. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contai... | 09/29/2009 |
| 7595049 | IGG1 monoclonal antibody with anti-HIV neutralizing activity The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epit... | 09/29/2009 |
| 7566451 | Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope ... | 07/28/2009 |
| 7306798 | Immunoglobulin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same The invention relates to a novel variant of isolated and/or purified immunoglobulin IgG3 which can be used as a marker for protecting against infectious viral diseases such as AIDS, as a diagnostic tool, or as a preventive and curative medicament. The invention also... | 12/11/2007 |
| 7226429 | Method for removal of viruses from blood by lectin affinity hemodialysis The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Acc... | 06/05/2007 |
| 7223844 | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody ... | 05/29/2007 |
| 7220411 | Compositions comprising anti-CCR5 antibody This invention provides a composition for inhibiting HIV-1 infection comprising at least two compounds in synergistically effective amounts for inhibiting HIV-1 infection, wherein at least one of the compounds prevents the productive interaction between HIV-1 and an... | 05/22/2007 |
| 7122188 | Antibodies which bind with proteins of human immunodeficiency virus type 1 (HIV-1), and immune complexes comprising proteins of HIV-1 This invention provides antibodies which bind with p12 and p18 proteins of a human immunodeficiency virus type 1 (HIV-1), antibodies which bind with immune complexes comprising p12 or p18 proteins of HIV-1, mixtures of antibodies which bind with p12, p15, p18, p25, ... | 10/17/2006 |
| 7060273 | Methods for inhibiting HIV-1 infection This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 ... | 06/13/2006 |
| 7045130 | Antibodies against antigens of human immunodeficiency virus (HIV-1) This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus... | 05/16/2006 |
| 7041293 | HIV env antibodies The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro. ... | 05/09/2006 |
| 7008622 | Methods and compositions for impairing multiplication of HIV-1 A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and... | 03/07/2006 |
| 6803449 | Nef-attachable protein A monoclonal antibody specific to Nap was prepared by using a crude membrane fraction from a cell line which has a high affinity to Nef as an antigen. A cDNA clone which encodes Nap was obtained by screening a cDNA library of said cell line utilizing the specific an... | 10/12/2004 |
| 6703019 | Cationized antibodies against intracellular proteins The subject application discloses methods and compositions for the targeted detection and/or inhibition of an intracellular protein in a cell by contacting the cell with a cationized antibody which reacts specifically with the intracellular protein. An ex... | 03/09/2004 |
| 6673342 | Recombinant human IgA-J chain dimer Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such a... | 01/06/2004 |
| 6623738 | Semaphorin receptors The invention provides methods and compositions relating to two classes of semaphorin receptors, SR1 and SR2. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SR encoding nucleic acids or purified from human ce... | 09/23/2003 |
| 6610833 | Monoclonal human natural antibodies Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formula... | 08/26/2003 |
| 6596478 | Method and composition to detect C-type retroviral infection The present invention comprises methods, devices and compositions for detection of endogenous retroviruses found in xenotransplant materials. The methods and compositions are suited for detection of endogenous type-C retroviruses and in particular, for po... | 07/22/2003 |
| 6565849 | Methods of enhancing activity of vaccines and vaccine compositions Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are me... | 05/20/2003 |
| 6545128 | Anti-bax inhibitor protein antibodies The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid molecules complementary thereto (SEQ ID NO: 2 and SEQ ID NO: 5... | 04/08/2003 |
| 6503753 | Method for the development of an HIV vaccine Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation. The inactivated virus may be more safely handled, stored, and analyzed, used in diagnostic procedures and kits, and may be used as an immunogen to evoke ... | 01/07/2003 |
| 6440416 | Vaccines against cancer and infectious diseases A method of stimulating an immune response in a human against malignant cells or an infectious agent comprises the step of administering to the human an immunogenic amount of a primate anti-idiotype antibody or antibody fragment that acts as an immunogeni... | 08/27/2002 |
| 6395275 | Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus The present invention describes synthetic human monoclonal antibodies that immunoreact with and neutralize human immunodeficiency virus (HIV). The synthetic monoclonal antibodies of this invention exhibit enhanced binding affinity and neutralization abili... | 05/28/2002 |
| 6261558 | Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus The present invention describes synthetic human monoclonal antibodies that immunoreact with and neutralize human immunodeficiency virus (HIV). The synthetic monoclonal antibodies of this invention exhibit enhanced binding affinity and neutralization abili... | 07/17/2001 |
| 6248332 | Targeted immunostimulation with bispecific reagents Disclosed are methods of stimulating in a subject an immune response to an antigen to which the immune response is targeted. This method includes the step of administering to the subject a binding agent which binds a surface receptor of an antigen-present... | 06/19/2001 |
| 6241986 | Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV Human monoclonal antibodies specific for the CD4-binding domain of HIV gp120 are useful in the neutralization of HIV and in the prevention of HIV infection and the treatment of a subject infected with HIV. Such antibodies and heterohybridomas producing th... | 06/05/2001 |
| 6228361 | IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use The present invention provides a human-mouse myeloma analog, designated HMMA 2.11TG/O, which has been deposited with the American Type Culture Collection (ATCC) under Accession Number HB 9583. The invention also provides a hybridoma designated F 105, whic... | 05/08/2001 |
| 6190871 | Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type I (HIV-1) gp120 and methods of use The invention features immunoreagents which neutralize the Human Immunodeficiency Virus Type 1 (HIV-1) by binding to a novel conserved epitope of the HIV-1 gp120. These immunoreagents exhibit a broad neutralizing effect upon HIV attachment to host cells, ... | 02/20/2001 |
| 6146628 | Biotherapeutic agents comprising recombinant PAP and PAP mutants Biotherapeutic agents are provided which comprise recombinant PAP or a biologically equivalent variant or mutant thereof, linked to a targeting moiety which are effective for the treatment of certain human diseases. The invention further provides a proces... | 11/14/2000 |
| 6140043 | Pharmaceutical compositions for competitively inhibiting the binding of a retrovirus to the IFN-receptor and means for diagnosis of an HIV infection The present invention is based on the observation that HIV does not only interact with the CD4 receptor of target cells but that there exists a different type of interaction between HIV envelope protein and the IFN receptor of the target cell. Thus, block... | 10/31/2000 |
| 6103238 | Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines Selective deglycosylation of HIV-1 envelope proteins enhances their ability to elicit a protective immune response in people. Glycosylation can reduce or prevent immunological recognition of envelope protein domains. Selective deglycosylation exposes thes... | 08/15/2000 |
| 6096312 | Agent for suppressing a reduction of CD4+ lymphocytes An agent for preventing or treating AIDS which contains as its effective component an anti-Fas ligand antibody, and the method for preventing and treating AIDS by using such drug.... | 08/01/2000 |
| 6066323 | Use of antibodies to sialidase as anti-infectious agents and anti-inflammatory agents Sialic acids have the ability to prevent hyposialylation of cells as comptive inhibitors of endogenous sialidase. It is now also possible to develop antibodies to mammalian sialidase that significantly reduce influx of neutrophils into inflammatory sites... | 05/23/2000 |
| 6001977 | Cloning and expression of HTLV-III DNA The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant,DNA methods and production of viral RNA are disclosed. Such polypeptides c... | 12/14/1999 |
| 5976522 | Lymphocyte chemoattractant factor and uses thereof Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.... | 11/02/1999 |
| 5965120 | Lymphocyte chemoattractant factor and uses thereof Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.... | 10/12/1999 |
| 5962635 | Therapeutic compounds A biologically-active peptide fragment of the Nef protein of human immunodeficiency virus is provided, pharmaceutical compositions comprising the peptide, analogs or derivatives of the peptide and therepeutic and screening methods which utilize the peptid... | 10/05/1999 |
